Drugs / KSD-101
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06752473 | Jan 2025 → Sep 2026 overdue | Epstein-Barr virus infection, nasopharyngeal carcinoma | Kousai Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06370026 | May 2024 → Dec 2025 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06097793 | Dec 2023 → Dec 2024 | nasopharyngeal carcinoma | Kousai Bio Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT05882305 | Jun 2023 → Dec 2024 | lymphoma | Kousai Bio Co., Ltd. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 12 trials | ||||||
| Phase 1 | NCT07532746 | May 2026 → Dec 2028 expected | Epstein-Barr virus-related tumor | Kousai Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05635591 | Jan 2023 → Dec 2026 expected | Epstein-Barr virus-related tumor | Tongji Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSD-101 | “The primary objectives of this study is to evaluate the tolerability and safety of KSD-101 in Patients with EBV-associated haematologic neoplasms, observe the dose-limiting...” NCT05635591 ↗5“KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial” NCT05882305 ↗ |
| Modality | Cell therapy | “Autologous monocyte - derived DCs pulsed with EBV antigen” NCT05635591 ↗ |
| Route | Subcutaneous | “via subcutaneous injections” NCT05635591 ↗ |